Literature DB >> 16814565

Expression and purification of His-tagged HPV16 E7 protein active in pRb binding.

Ewa A Mirecka1, Rainer Rudolph, Thomas Hey.   

Abstract

Human papillomavirus type 16 (HPV16) protein E7 is the major oncogenic factor associated with the development of human cervical cancer. The transforming activity of the E7 protein is linked to its interaction with host regulatory proteins such as the retinoblastoma tumor suppressor protein. The recombinant production of E7 protein is a prerequisite for its structural and functional characterization as well as for the development of various preventive and therapeutic strategies. We present an approach to enhance the soluble expression of His-tagged E7 protein by optimization of the E7 gene and the expression conditions in the host Escherichia coli. We also report a detailed protocol for the purification of E7 protein by standard chromatographic methods. The binding of E7 protein to the recombinant non-phosphorylated form of retinoblastoma protein was examined by ELISA and surface plasmon resonance analysis. These studies confirm that the recombinant His-tagged E7 protein retains its conformational properties and biological activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16814565     DOI: 10.1016/j.pep.2006.04.017

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Malonyl-CoA synthetase, encoded by ACYL ACTIVATING ENZYME13, is essential for growth and development of Arabidopsis.

Authors:  Hui Chen; Hyun Uk Kim; Hua Weng; John Browse
Journal:  Plant Cell       Date:  2011-06-03       Impact factor: 11.277

2.  Orf Virus-Based Therapeutic Vaccine for Treatment of Papillomavirus-Induced Tumors.

Authors:  M Schneider; M Müller; A Yigitliler; J Xi; C Simon; T Feger; H-J Rziha; F Stubenrauch; H-G Rammensee; T Iftner; R Amann
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

3.  Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal model.

Authors:  Linda Petrone; Maria G Ammendolia; Armando Cesolini; Stefano Caimi; Fabiana Superti; Colomba Giorgi; Paola Di Bonito
Journal:  J Transl Med       Date:  2011-05-18       Impact factor: 5.531

4.  Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model.

Authors:  Xuan Wang; Fang-Cheng Zhang; Hong-Yang Zhao; Xiao-Ling Lu; Yun Sun; Zhi-Yong Xiong; Xiao-Bing Jiang
Journal:  Tumour Biol       Date:  2014-05-10

Review 5.  Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.

Authors:  Zeinab Shirbaghaee; Azam Bolhassani
Journal:  Biopolymers       Date:  2016-03       Impact factor: 2.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.